c-myc, c-erbB-1 and c-erbB-2 expressions in urothelial carcinoma
The expression of c‐myc, c‐erbB‐1 and c‐erbB‐2 In 24 cases of urothelial carcinoma by Southern and northern blot analysis, and immunohistochemistry was examined. The results were compared with the pathological grade and stage. We found elevated mRNA expressions of c‐myc and c‐erbB‐1 In 19 and 11 of...
Gespeichert in:
| Veröffentlicht in: | Pathology international 1997-04, Vol.47 (4), p.209-216 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 216 |
|---|---|
| container_issue | 4 |
| container_start_page | 209 |
| container_title | Pathology international |
| container_volume | 47 |
| creator | Onodera, Takafumi Hashlmoto, Yasuhlro Yaglhashi, Soroku |
| description | The expression of c‐myc, c‐erbB‐1 and c‐erbB‐2 In 24 cases of urothelial carcinoma by Southern and northern blot analysis, and immunohistochemistry was examined. The results were compared with the pathological grade and stage. We found elevated mRNA expressions of c‐myc and c‐erbB‐1 In 19 and 11 of 21 cases, respectively, but there was no apparent amplification or rearrangement of these oncogenes in any of the cases examined. By immunohistochemistry using anti‐epidermal growth factor receptor antibody, most of the cases showed positbe immunoreactivity on the cancer cell membranes, and cancers of higher pathological grade and stage showed more intense staining. By contrast, amplification of c‐erbB‐2 was detected in four of 24 cases, all of which were assigned to a high pathological grade (G3). Elevated c‐erbB‐2 mRNA levels appeared to correlate with the pathological grade of the cancers. Positive immunohistochemical reactions to c‐erbB‐2 were found in the cancer cell membranes in three of 24 cases, which were accompanied by amplification and eievated mRNA levels of c‐erbB‐2. In conclusion, expressions of c‐myc, c‐erbB‐1 and c‐erbB‐2 were all elevated in the majority of urothellal carcinomas, but the amplification was not universal. |
| doi_str_mv | 10.1111/j.1440-1827.1997.tb04482.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78960021</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78960021</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4599-dcc9669cc695e4d7feea616e7c8b23d17eba3615041d4b0c9e0b6701e6ff18723</originalsourceid><addsrcrecordid>eNqVkE1PGzEQhq2qiALtT6i04tATXjy21173ULVEfJaPqCqi6sXyemfFhv0IdiKSf89GCbkzF4_1zjwjPYQcAkthqONJClIyCjnXKRij01nBpMx5uvhA9rbRx6EXnNFMKvGJ7Mc4YQy0UGyX7BpgggPskZ-etkt_lHiKoTihkLiufPvwBBfTgDHWfReTukvmoZ89YlO7JvEu-LrrW_eZ7FSuifhl8x6Q-7PTv6MLen13fjn6dU29zIyhpfdGKeO9MhnKUleIToFC7fOCixI0Fk4oyJiEUhbMG2SF0gxQVRXkmosD8m3NnYb-eY5xZts6emwa12E_j1bnRjHGYRj8vh70oY8xYGWnoW5dWFpgdqXPTuzKkV05sit9dqPPLoblr5sr86LFcru68TXkP9b5S93g8h1kO7685cwMALoG1HGGiy3AhSertNCZfbg9t7___b8Zj67-2LF4BSJjjWk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78960021</pqid></control><display><type>article</type><title>c-myc, c-erbB-1 and c-erbB-2 expressions in urothelial carcinoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Onodera, Takafumi ; Hashlmoto, Yasuhlro ; Yaglhashi, Soroku</creator><creatorcontrib>Onodera, Takafumi ; Hashlmoto, Yasuhlro ; Yaglhashi, Soroku</creatorcontrib><description>The expression of c‐myc, c‐erbB‐1 and c‐erbB‐2 In 24 cases of urothelial carcinoma by Southern and northern blot analysis, and immunohistochemistry was examined. The results were compared with the pathological grade and stage. We found elevated mRNA expressions of c‐myc and c‐erbB‐1 In 19 and 11 of 21 cases, respectively, but there was no apparent amplification or rearrangement of these oncogenes in any of the cases examined. By immunohistochemistry using anti‐epidermal growth factor receptor antibody, most of the cases showed positbe immunoreactivity on the cancer cell membranes, and cancers of higher pathological grade and stage showed more intense staining. By contrast, amplification of c‐erbB‐2 was detected in four of 24 cases, all of which were assigned to a high pathological grade (G3). Elevated c‐erbB‐2 mRNA levels appeared to correlate with the pathological grade of the cancers. Positive immunohistochemical reactions to c‐erbB‐2 were found in the cancer cell membranes in three of 24 cases, which were accompanied by amplification and eievated mRNA levels of c‐erbB‐2. In conclusion, expressions of c‐myc, c‐erbB‐1 and c‐erbB‐2 were all elevated in the majority of urothellal carcinomas, but the amplification was not universal.</description><identifier>ISSN: 1320-5463</identifier><identifier>EISSN: 1440-1827</identifier><identifier>DOI: 10.1111/j.1440-1827.1997.tb04482.x</identifier><identifier>PMID: 9103211</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Blotting, Northern ; Blotting, Southern ; c-erbB-1 ; c-erbB-2 ; c-myc ; Carcinoma - chemistry ; Carcinoma - metabolism ; Carcinoma - pathology ; Cell Membrane - chemistry ; Epidermal Growth Factor - analysis ; Epidermal Growth Factor - immunology ; Humans ; Immunohistochemistry ; Mucous Membrane - chemistry ; Mucous Membrane - pathology ; Proto-Oncogene Proteins c-myc - biosynthesis ; Receptor, Epidermal Growth Factor - biosynthesis ; Receptor, ErbB-2 - biosynthesis ; RNA, Messenger - biosynthesis ; RNA, Messenger - chemistry ; urinary tract cancer ; Urologic Neoplasms - chemistry ; Urologic Neoplasms - metabolism ; Urologic Neoplasms - pathology</subject><ispartof>Pathology international, 1997-04, Vol.47 (4), p.209-216</ispartof><rights>1997 The Japanese Society of Pathology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4599-dcc9669cc695e4d7feea616e7c8b23d17eba3615041d4b0c9e0b6701e6ff18723</citedby><cites>FETCH-LOGICAL-c4599-dcc9669cc695e4d7feea616e7c8b23d17eba3615041d4b0c9e0b6701e6ff18723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1440-1827.1997.tb04482.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1440-1827.1997.tb04482.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9103211$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Onodera, Takafumi</creatorcontrib><creatorcontrib>Hashlmoto, Yasuhlro</creatorcontrib><creatorcontrib>Yaglhashi, Soroku</creatorcontrib><title>c-myc, c-erbB-1 and c-erbB-2 expressions in urothelial carcinoma</title><title>Pathology international</title><addtitle>Pathol Int</addtitle><description>The expression of c‐myc, c‐erbB‐1 and c‐erbB‐2 In 24 cases of urothelial carcinoma by Southern and northern blot analysis, and immunohistochemistry was examined. The results were compared with the pathological grade and stage. We found elevated mRNA expressions of c‐myc and c‐erbB‐1 In 19 and 11 of 21 cases, respectively, but there was no apparent amplification or rearrangement of these oncogenes in any of the cases examined. By immunohistochemistry using anti‐epidermal growth factor receptor antibody, most of the cases showed positbe immunoreactivity on the cancer cell membranes, and cancers of higher pathological grade and stage showed more intense staining. By contrast, amplification of c‐erbB‐2 was detected in four of 24 cases, all of which were assigned to a high pathological grade (G3). Elevated c‐erbB‐2 mRNA levels appeared to correlate with the pathological grade of the cancers. Positive immunohistochemical reactions to c‐erbB‐2 were found in the cancer cell membranes in three of 24 cases, which were accompanied by amplification and eievated mRNA levels of c‐erbB‐2. In conclusion, expressions of c‐myc, c‐erbB‐1 and c‐erbB‐2 were all elevated in the majority of urothellal carcinomas, but the amplification was not universal.</description><subject>Blotting, Northern</subject><subject>Blotting, Southern</subject><subject>c-erbB-1</subject><subject>c-erbB-2</subject><subject>c-myc</subject><subject>Carcinoma - chemistry</subject><subject>Carcinoma - metabolism</subject><subject>Carcinoma - pathology</subject><subject>Cell Membrane - chemistry</subject><subject>Epidermal Growth Factor - analysis</subject><subject>Epidermal Growth Factor - immunology</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Mucous Membrane - chemistry</subject><subject>Mucous Membrane - pathology</subject><subject>Proto-Oncogene Proteins c-myc - biosynthesis</subject><subject>Receptor, Epidermal Growth Factor - biosynthesis</subject><subject>Receptor, ErbB-2 - biosynthesis</subject><subject>RNA, Messenger - biosynthesis</subject><subject>RNA, Messenger - chemistry</subject><subject>urinary tract cancer</subject><subject>Urologic Neoplasms - chemistry</subject><subject>Urologic Neoplasms - metabolism</subject><subject>Urologic Neoplasms - pathology</subject><issn>1320-5463</issn><issn>1440-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkE1PGzEQhq2qiALtT6i04tATXjy21173ULVEfJaPqCqi6sXyemfFhv0IdiKSf89GCbkzF4_1zjwjPYQcAkthqONJClIyCjnXKRij01nBpMx5uvhA9rbRx6EXnNFMKvGJ7Mc4YQy0UGyX7BpgggPskZ-etkt_lHiKoTihkLiufPvwBBfTgDHWfReTukvmoZ89YlO7JvEu-LrrW_eZ7FSuifhl8x6Q-7PTv6MLen13fjn6dU29zIyhpfdGKeO9MhnKUleIToFC7fOCixI0Fk4oyJiEUhbMG2SF0gxQVRXkmosD8m3NnYb-eY5xZts6emwa12E_j1bnRjHGYRj8vh70oY8xYGWnoW5dWFpgdqXPTuzKkV05sit9dqPPLoblr5sr86LFcru68TXkP9b5S93g8h1kO7685cwMALoG1HGGiy3AhSertNCZfbg9t7___b8Zj67-2LF4BSJjjWk</recordid><startdate>199704</startdate><enddate>199704</enddate><creator>Onodera, Takafumi</creator><creator>Hashlmoto, Yasuhlro</creator><creator>Yaglhashi, Soroku</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199704</creationdate><title>c-myc, c-erbB-1 and c-erbB-2 expressions in urothelial carcinoma</title><author>Onodera, Takafumi ; Hashlmoto, Yasuhlro ; Yaglhashi, Soroku</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4599-dcc9669cc695e4d7feea616e7c8b23d17eba3615041d4b0c9e0b6701e6ff18723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Blotting, Northern</topic><topic>Blotting, Southern</topic><topic>c-erbB-1</topic><topic>c-erbB-2</topic><topic>c-myc</topic><topic>Carcinoma - chemistry</topic><topic>Carcinoma - metabolism</topic><topic>Carcinoma - pathology</topic><topic>Cell Membrane - chemistry</topic><topic>Epidermal Growth Factor - analysis</topic><topic>Epidermal Growth Factor - immunology</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Mucous Membrane - chemistry</topic><topic>Mucous Membrane - pathology</topic><topic>Proto-Oncogene Proteins c-myc - biosynthesis</topic><topic>Receptor, Epidermal Growth Factor - biosynthesis</topic><topic>Receptor, ErbB-2 - biosynthesis</topic><topic>RNA, Messenger - biosynthesis</topic><topic>RNA, Messenger - chemistry</topic><topic>urinary tract cancer</topic><topic>Urologic Neoplasms - chemistry</topic><topic>Urologic Neoplasms - metabolism</topic><topic>Urologic Neoplasms - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Onodera, Takafumi</creatorcontrib><creatorcontrib>Hashlmoto, Yasuhlro</creatorcontrib><creatorcontrib>Yaglhashi, Soroku</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pathology international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Onodera, Takafumi</au><au>Hashlmoto, Yasuhlro</au><au>Yaglhashi, Soroku</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>c-myc, c-erbB-1 and c-erbB-2 expressions in urothelial carcinoma</atitle><jtitle>Pathology international</jtitle><addtitle>Pathol Int</addtitle><date>1997-04</date><risdate>1997</risdate><volume>47</volume><issue>4</issue><spage>209</spage><epage>216</epage><pages>209-216</pages><issn>1320-5463</issn><eissn>1440-1827</eissn><abstract>The expression of c‐myc, c‐erbB‐1 and c‐erbB‐2 In 24 cases of urothelial carcinoma by Southern and northern blot analysis, and immunohistochemistry was examined. The results were compared with the pathological grade and stage. We found elevated mRNA expressions of c‐myc and c‐erbB‐1 In 19 and 11 of 21 cases, respectively, but there was no apparent amplification or rearrangement of these oncogenes in any of the cases examined. By immunohistochemistry using anti‐epidermal growth factor receptor antibody, most of the cases showed positbe immunoreactivity on the cancer cell membranes, and cancers of higher pathological grade and stage showed more intense staining. By contrast, amplification of c‐erbB‐2 was detected in four of 24 cases, all of which were assigned to a high pathological grade (G3). Elevated c‐erbB‐2 mRNA levels appeared to correlate with the pathological grade of the cancers. Positive immunohistochemical reactions to c‐erbB‐2 were found in the cancer cell membranes in three of 24 cases, which were accompanied by amplification and eievated mRNA levels of c‐erbB‐2. In conclusion, expressions of c‐myc, c‐erbB‐1 and c‐erbB‐2 were all elevated in the majority of urothellal carcinomas, but the amplification was not universal.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>9103211</pmid><doi>10.1111/j.1440-1827.1997.tb04482.x</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1320-5463 |
| ispartof | Pathology international, 1997-04, Vol.47 (4), p.209-216 |
| issn | 1320-5463 1440-1827 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78960021 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Blotting, Northern Blotting, Southern c-erbB-1 c-erbB-2 c-myc Carcinoma - chemistry Carcinoma - metabolism Carcinoma - pathology Cell Membrane - chemistry Epidermal Growth Factor - analysis Epidermal Growth Factor - immunology Humans Immunohistochemistry Mucous Membrane - chemistry Mucous Membrane - pathology Proto-Oncogene Proteins c-myc - biosynthesis Receptor, Epidermal Growth Factor - biosynthesis Receptor, ErbB-2 - biosynthesis RNA, Messenger - biosynthesis RNA, Messenger - chemistry urinary tract cancer Urologic Neoplasms - chemistry Urologic Neoplasms - metabolism Urologic Neoplasms - pathology |
| title | c-myc, c-erbB-1 and c-erbB-2 expressions in urothelial carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T03%3A43%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=c-myc,%20c-erbB-1%20and%20c-erbB-2%20expressions%20in%20urothelial%20carcinoma&rft.jtitle=Pathology%20international&rft.au=Onodera,%20Takafumi&rft.date=1997-04&rft.volume=47&rft.issue=4&rft.spage=209&rft.epage=216&rft.pages=209-216&rft.issn=1320-5463&rft.eissn=1440-1827&rft_id=info:doi/10.1111/j.1440-1827.1997.tb04482.x&rft_dat=%3Cproquest_cross%3E78960021%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78960021&rft_id=info:pmid/9103211&rfr_iscdi=true |